Posted by Michael Wonder on 20 Dec 2022
Ezharmia launched in Japan as first dual EZH1 and EZH2 inhibitor therapy for patients with adult T-cell leukaemia-lymphoma
20 December 2022 - Ezharmia is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Daiichi Sankyo today announced the launch of Ezhermia (valemetostat tosilate), a first in class dual inhibitor of EZH1 and EZH2, in Japan for the treatment of adult patients with relapsed or refractory T-cell leukaemia lymphoma.
